I Borget

Summary

Affiliation: Institut Gustave Roussy
Country: France

Publications

  1. ncbi request reprint Sick leave for follow-up control in thyroid cancer patients: comparison between stimulation with Thyrogen and thyroid hormone withdrawal
    I Borget
    Department of Health Economics, Institut de Cancerologie Gustave Roussy, 39 rue Camille Desmoulins, 94805 Villejuif, France
    Eur J Endocrinol 156:531-8. 2007
  2. doi request reprint Length and cost of hospital stay of radioiodine ablation in thyroid cancer patients: comparison between preparation with thyroid hormone withdrawal and thyrogen
    I Borget
    Detpartment of Health Economics, Institut Gustave Roussy, 39 rue Camille Desmoulins, 94805, Villejuif, France
    Eur J Nucl Med Mol Imaging 35:1457-63. 2008
  3. doi request reprint Early changes in carcinoembryonic antigen but not in calcitonin levels are correlated with the progression-free survival in medullary thyroid carcinoma patients treated with cytotoxic chemotherapy
    G Hajje
    Department of Nuclear Medicine and Endocrine Tumors, Institut Gustave Roussy, University Paris Sud, 39 rue Camille Desmoulins, 94805 Villejuif Cedex, France
    Eur J Endocrinol 168:113-8. 2013
  4. doi request reprint Long-term follow-up of patients with papillary and follicular thyroid cancer: a prospective study on 715 patients
    M Brassard
    Department of Nuclear Medicine and Endocrine Oncology, Institut Gustave Roussy, 94805 Villejuif, France
    J Clin Endocrinol Metab 96:1352-9. 2011
  5. ncbi request reprint [Biosimilars and medico-economic aspects]
    I Borget
    Institut Gustave Roussy, Etudes et Recherche en Economie de la Santé, 39 rue Camille Desmoulins, 94805 Villejuif Cedex, France
    Bull Cancer 97:589-95. 2010
  6. doi request reprint Therapeutic management of advanced adrenocortical carcinoma: what do we know in 2011?
    E Baudin
    Department of Nuclear Medicine and Endocrine Tumors, Institut Gustave Roussy, Univ Paris Sud, Villejuif, France
    Horm Cancer 2:363-71. 2011
  7. doi request reprint Cost-effectiveness of three strategies for second-line erlotinib initiation in nonsmall-cell lung cancer: the ERMETIC study part 3
    I Borget
    Etudes et Recherche en Economie de la Santé, Institut Gustave Roussy, 39 rue Camille Desmoulins, 94805 Villejuif Cedex, France
    Eur Respir J 39:172-9. 2012
  8. doi request reprint Persistent disease and recurrence in differentiated thyroid cancer patients with undetectable postoperative stimulated thyroglobulin level
    C Nascimento
    Department of Nuclear Medicine and Endocrine Oncology, Institut Gustave Roussy, Univ Paris Sud, Villejuif, France
    Endocr Relat Cancer 18:R29-40. 2011
  9. doi request reprint Economic burden of HPV-related cancers in France
    I Borget
    Gustave Roussy Institute, Villejuif, France
    Vaccine 29:5245-9. 2011
  10. ncbi request reprint [A prospective study of quality of life and treatment of chemotherapy-induced anaemia in lung cancer]
    I Borget
    Services de pharmacie, Hopital Saint Antoine, Paris, France
    Rev Mal Respir 24:41-7. 2007

Detail Information

Publications10

  1. ncbi request reprint Sick leave for follow-up control in thyroid cancer patients: comparison between stimulation with Thyrogen and thyroid hormone withdrawal
    I Borget
    Department of Health Economics, Institut de Cancerologie Gustave Roussy, 39 rue Camille Desmoulins, 94805 Villejuif, France
    Eur J Endocrinol 156:531-8. 2007
    ..This study compared the frequency, the duration and the cost of sick leave for follow-up control between rhTSH and withdrawal...
  2. doi request reprint Length and cost of hospital stay of radioiodine ablation in thyroid cancer patients: comparison between preparation with thyroid hormone withdrawal and thyrogen
    I Borget
    Detpartment of Health Economics, Institut Gustave Roussy, 39 rue Camille Desmoulins, 94805, Villejuif, France
    Eur J Nucl Med Mol Imaging 35:1457-63. 2008
    ..The aim of this study was to assess the financial impact of a reduced length of hospital stay with the use of rhTSH...
  3. doi request reprint Early changes in carcinoembryonic antigen but not in calcitonin levels are correlated with the progression-free survival in medullary thyroid carcinoma patients treated with cytotoxic chemotherapy
    G Hajje
    Department of Nuclear Medicine and Endocrine Tumors, Institut Gustave Roussy, University Paris Sud, 39 rue Camille Desmoulins, 94805 Villejuif Cedex, France
    Eur J Endocrinol 168:113-8. 2013
    ..The aim of this study was to evaluate, in patients with advanced MTC treated with cytotoxic chemotherapy, the relationship between early changes of serum CT or CEA levels and progression-free survival (PFS)...
  4. doi request reprint Long-term follow-up of patients with papillary and follicular thyroid cancer: a prospective study on 715 patients
    M Brassard
    Department of Nuclear Medicine and Endocrine Oncology, Institut Gustave Roussy, 94805 Villejuif, France
    J Clin Endocrinol Metab 96:1352-9. 2011
    ....
  5. ncbi request reprint [Biosimilars and medico-economic aspects]
    I Borget
    Institut Gustave Roussy, Etudes et Recherche en Economie de la Santé, 39 rue Camille Desmoulins, 94805 Villejuif Cedex, France
    Bull Cancer 97:589-95. 2010
    ..The differences existing between generics and biosimilars and their impact on costs will be presented. Finally, it will focus on the factors that may facilitate or limit the biosimilars development and their substitution...
  6. doi request reprint Therapeutic management of advanced adrenocortical carcinoma: what do we know in 2011?
    E Baudin
    Department of Nuclear Medicine and Endocrine Tumors, Institut Gustave Roussy, Univ Paris Sud, Villejuif, France
    Horm Cancer 2:363-71. 2011
    ..International networks and comprehensive databases gathering clinical and biological data constitute the prerequisites for progress...
  7. doi request reprint Cost-effectiveness of three strategies for second-line erlotinib initiation in nonsmall-cell lung cancer: the ERMETIC study part 3
    I Borget
    Etudes et Recherche en Economie de la Santé, Institut Gustave Roussy, 39 rue Camille Desmoulins, 94805 Villejuif Cedex, France
    Eur Respir J 39:172-9. 2012
    ..Sensitivity analyses confirmed the robustness of the results. The cost-effectiveness of second-line NSCLC treatment is improved when patients are selected on either clinical or biological grounds...
  8. doi request reprint Persistent disease and recurrence in differentiated thyroid cancer patients with undetectable postoperative stimulated thyroglobulin level
    C Nascimento
    Department of Nuclear Medicine and Endocrine Oncology, Institut Gustave Roussy, Univ Paris Sud, Villejuif, France
    Endocr Relat Cancer 18:R29-40. 2011
    ..In these patients, repeating TSH-Tg 6-18 months after ablation is not useful. (131)I ablation could be avoided in the absence of N1 and aggressive histological variant...
  9. doi request reprint Economic burden of HPV-related cancers in France
    I Borget
    Gustave Roussy Institute, Villejuif, France
    Vaccine 29:5245-9. 2011
    ..5 million, due mainly to invasive cervical cancer (€83.9 million). The costs associated with HPV-related cancers are important to consider when evaluating the overall benefits of HPV vaccination in males and females...
  10. ncbi request reprint [A prospective study of quality of life and treatment of chemotherapy-induced anaemia in lung cancer]
    I Borget
    Services de pharmacie, Hopital Saint Antoine, Paris, France
    Rev Mal Respir 24:41-7. 2007
    ..The impact of chemotherapy-induced anemia on the quality of life (QOL) of patients with lung cancer has been little studied...